KCI’s VAC VeraFlo Therapy shows benefits in new study

KCI has highlighted data from an independent retrospective study that demonstrates the significant benefits offered by its VAC VeraFlo Therapy.

The research, which was published in the journal Plastic and Reconstructive Surgery, showed that adjunctive VAC VeraFlo treatment using the VAC Ulta Negative Pressure Wound Therapy System offered several key advantages over traditional VAC therapy.

These included statistically significant decreases in operating room (OR) visits, time to final surgical procedure and length of stay. As such, the results suggest that adding instillation treatment to negative pressure wound therapy enhances its effectiveness.

It was the largest study yet conducted into impact of negative pressure with instillation on wounds requiring surgical intervention for the treatment of infection.

Joe Woody, president and chief executive officer at KCI, said: "This research suggests that VAC VeraFlo Therapy has the potential to help significantly improve the patient experience and reduce the cost of care associated with lengthy hospital stays, multiple OR visits and additional procedures."

This comes after VAC VeraFlo Instillation Therapy was also recently recommended in a supplement published in the International Wound Journal earlier this year.